Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3500 in Moderate-to-Severe Atopic Dermatitis (Phase 2b, Dose-Ranging)
2018-001544-64Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing REGN3500 monotherapy with Placebo (2 arms). Primary endpoint: Percent change in EASI score from baseline to week 16. Started Jan 2019; status: terminated.
02
Drugs
itepekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-001544-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001544-64.